Deal Watch: Pfizer Begins 2018 With Two Deals, Including ALS Tie-Up With Sangamo
In addition to its latest collaboration with Sangamo, Pfizer also teams with Arvinas on protein-degradation therapies. AstraZeneca sells off four mature products to ANI, while Summit enhances its antibiotic capabilities with Discuva buyout and out-licenses Latin American rights to ridinilazole.
You may also be interested in...
Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.
Five Prime’s Phase III-ready bemarituzumab could offer significant revenue for Amgen, particularly in Asia, but analysts ask if the buyout is a precursor to greater deal making by Amgen.
A potential first-in-class FGFR2b-targeted monoclonal antibody, bemarituzumab, has shown top-line benefits in the Phase II FIGHT study in advanced gastric or gastroesophageal junction cancers.